Tanya Wildes MD on Twitter: "Noopur Raje: RVD-lite yields ORR 90% & 1year PFS >90%. Very promising for our most vulnerable older MM patients! #ASH16 #GeriOnc #mmsm https://t.co/nPIYokepSu" / Twitter
Role of Anti–CD38 Antibody Therapy in Induction and Maintenance in Newly Diagnosed Multiple Myeloma: How to Adopt in Clinical Practice
Debate: Standard induction for myeloma - RVD - YouTube
Treatment schema for newly diagnosed multiple myeloma and commonly used... | Download Scientific Diagram
Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Mye
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. - Abstract - Europe PMC
Management of Multiple Myeloma in Older Patients - European Medical Journal
NCCP Regimen 00781 Bortezomib and Lenalidomide (RVD-Lite) Consolidation Therapy Myeloma
Treatment Considerations for Transplant-Ineligible Multiple Myeloma
Optimizing Frontline Care for Older Patients With Multiple Myeloma (Transcript)
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma - O'Donnell - 2018 - British Journal of Haematology - Wiley Online Library